Ryvu Therapeutics S.A.
RVU.WA · WSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | PLN 890,126 | PLN 1,293,750 | PLN 902,976 | PLN 1,119,684 |
| - Cash | PLN 160,073 | PLN 57,939 | PLN 101,917 | PLN 83,236 |
| + Debt | PLN 75,514 | PLN 906 | PLN 2,768 | PLN 5,070 |
| Enterprise Value | PLN 805,567 | PLN 1,236,717 | PLN 803,827 | PLN 1,041,518 |
| Revenue | PLN 77,968 | PLN 46,860 | PLN 38,804 | PLN 11,186 |
| % Growth | 66.4% | 20.8% | 246.9% | – |
| Gross Profit | PLN 58,388 | PLN 29,306 | PLN 21,398 | -PLN 2,539 |
| % Margin | 74.9% | 62.5% | 55.1% | -22.7% |
| EBITDA | -PLN 96,834 | -PLN 81,044 | -PLN 65,206 | -PLN 65,959 |
| % Margin | -124.2% | -172.9% | -168% | -589.6% |
| Net Income | -PLN 111,435 | -PLN 92,112 | -PLN 83,782 | -PLN 79,078 |
| % Margin | -142.9% | -196.6% | -215.9% | -706.9% |
| EPS Diluted | -4.82 | -4.02 | -4.57 | -4.31 |
| % Growth | -19.9% | 12% | -6% | – |
| Operating Cash Flow | -PLN 129,479 | -PLN 84,550 | PLN 21,319 | -PLN 57,868 |
| Capital Expenditures | -PLN 5,903 | -PLN 8,579 | -PLN 9,287 | -PLN 11,982 |
| Free Cash Flow | -PLN 135,382 | -PLN 88,114 | PLN 12,032 | -PLN 69,850 |